BP
The startup develops antimicrobial drugs specifically targeting chronic infections and biofilm-induced antibiotic resistance, focusing on the long-term treatment of diabetic foot ulcers. By re-engineering antimicrobials, the company enables pharmacists to effectively prevent metastatic bacterial infections, improving patient outcomes in chronic disease management.
Updated 3 months ago
Funding
$33.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antimicrobial drugs specifically targeting chronic infections and biofilm-induced antibiotic resistance, focusing on the long-term treatment of diabetic foot ulcers. By re-engineering antimicrobials, the company enables pharmacists to effectively prevent metastatic bacterial infections, improving patient outcomes in chronic disease management.